Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today.
Category: NYSE:BMY
Think Generics Will Lower the Cost of Chemo? Think Again
Chemotherapy drugs have become ridiculously expensive. Fortunately, many expensive cancer drugs are going off patent soon, raising hopes that generic alternatives will significantly lower patients’ expenses. However, a recent study suggests our hopes m…
Can The Record Breaking Number Of FDA New Drug Approvals Continue?
Despite these possibilities, the boom in new drugs is likely to continue benefiting the industry and more importantly, the patients anxiously waiting for these new treatments.
Global M&A Slips Despite Record Private Equity Activity
Intensifying trade tensions, political instability, and increased regulatory scrutiny took their toll on global M&A activity in 2018. The number of deals struck over the year fell slightly for the first time since 2010 to 19,232 after steadily rising f…
Lessons From The Biggest Pharma Drug Launches Of All Time
But given the medical breakthroughs being made, it is likely that in the coming years there will be new entries in this list – and high priced ones at that.
How To Really Take Medical Conflicts Of Interest Seriously
If we’re going to have a central database of conflict of interest disclosures in medicine – and there is one, created by law – it’s high time that people start using it.
FDA’s New Generic EpiPen Approval Exemplifies Progress on Drug Price Reform
Last week, FDA Commissioner Scott Gottlieb announced the approval of the first generic version of EpiPen, an injectable form of epinephrine used in children to treat life-threatening allergies. Under Gottlieb and HHS Secretary Alex Azar, the consistent…
